Volume 16, Issue 3, Pages (March 2008)

Slides:



Advertisements
Similar presentations
Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector  Wei Huang, Travis McMurphy,
Advertisements

Volume 3, Issue 5, Pages (May 2001)
Volume 16, Issue 3, Pages (March 2008)
Volume 2, Issue 1, Pages (July 2000)
Volume 8, Issue 2, Pages (August 2003)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Molecular Therapy - Methods & Clinical Development
Volume 21, Issue 12, Pages (December 2013)
Volume 14, Issue 1, Pages (July 2006)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Transient Gene Expression by Nonintegrating Lentiviral Vectors
Volume 16, Issue 2, Pages (February 2008)
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
Molecular Therapy - Methods & Clinical Development
Volume 13, Issue 2, Pages (February 2006)
Volume 2, Issue 1, Pages (July 2000)
Volume 9, Issue 4, Pages (April 2004)
Molecular Therapy - Methods & Clinical Development
A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae  Yang Wu, Liangyu Jiang,
Gene delivery to in situ veins: Differential effects of adenovirus and adeno-associated viral vectors  Mohammad H. Eslami, MD, Sidhu P. Gangadharan, MD,
Volume 15, Issue 2, Pages (February 2007)
Volume 2, Issue 3, Pages (September 2000)
Molecular Therapy - Methods & Clinical Development
High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing  Damien Marsic, Héctor R Méndez-Gómez, Sergei Zolotukhin 
Volume 17, Issue 2, Pages (February 2009)
Volume 19, Issue 3, Pages (March 2011)
Volume 22, Issue 11, Pages (November 2014)
Volume 15, Issue 1, Pages (January 2007)
Xiuwu Zhang, Chuan-Yuan Li  Molecular Therapy 
NILV‐S/MAR‐mediated transgene expression
Volume 23, Issue 10, Pages (October 2015)
Kailin Xu, Hong Ma, Thomas J. McCown, Inder M. Verma, Tal Kafri 
Volume 18, Issue 1, Pages (January 2010)
Volume 13, Issue 1, Pages (January 2006)
Volume 16, Issue 5, Pages (May 2008)
Volume 16, Issue 6, Pages (June 2008)
Molecular Therapy - Methods & Clinical Development
Improved Retinal Transduction In Vivo and Photoreceptor-specific Transgene Expression Using Adenovirus Vectors With Modified Penton Base  Siobhan M Cashman,
Volume 25, Issue 2, Pages (February 2017)
Volume 15, Issue 8, Pages (August 2007)
Volume 10, Issue 4, Pages (October 2004)
Volume 8, Issue 2, Pages (August 2003)
Volume 12, Issue 5, Pages (November 2005)
NILV‐S/MAR‐mediated transgene expression
Effect of Genome Size on AAV Vector Packaging
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
Volume 18, Issue 2, Pages (February 2010)
Volume 4, Issue 6, Pages (December 2001)
Volume 17, Issue 1, Pages (January 2009)
Volume 20, Issue 3, Pages (March 2012)
Volume 18, Issue 12, Pages (December 2010)
Volume 15, Issue 7, Pages (July 2007)
Volume 24, Issue 1, Pages (January 2016)
Volume 15, Issue 5, Pages (May 2007)
Development of a Novel Recombinant Adeno-Associated Virus Production System Using Human Bocavirus 1 Helper Genes  Zekun Wang, Fang Cheng, John F. Engelhardt,
Molecular Therapy - Methods & Clinical Development
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Volume 7, Issue 1, Pages (January 2003)
Molecular Therapy - Oncolytics
Zhijian Wu, Aravind Asokan, R. Jude Samulski  Molecular Therapy 
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno- Associated Virus Production and Their in Vivo Persistence after Vector Delivery 
Volume 15, Issue 9, Pages (September 2007)
Volume 8, Issue 1, Pages (July 2003)
Biao Dong, Hiroyuki Nakai, Weidong Xiao  Molecular Therapy 
Volume 9, Issue 4, Pages (April 2004)
Volume 13, Issue 1, Pages (January 2006)
Targeting expression of a transgene to the airway surface epithelium using a ciliated cell-specific promoter  Lawrence E Ostrowski, James R Hutchins,
Volume 22, Issue 11, Pages (November 2014)
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

Volume 16, Issue 3, Pages 494-499 (March 2008) Adeno-associated Virus of a Single-polarity DNA Genome Is Capable of Transduction In Vivo  Xiaohuai Zhou, Xinghua Zeng, Zhenghong Fan, Chengwen Li, Thomas McCown, R Jude Samulski, Xiao Xiao  Molecular Therapy  Volume 16, Issue 3, Pages 494-499 (March 2008) DOI: 10.1038/sj.mt.6300397 Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 1 Schematic representation of adeno-associated virus (AAV) terminal repeat deletions and production of polarity vectors. (a) Resolution and packaging of pDD series of plasmid. The plasmid is resolved at the Holiday junction to form a no-end DNA, which is subsequently converted into single-stranded genomes through the AAV replication process. Single-stranded genomes with intact D sequences at the 3′-end are efficiently packaged into viral particles; whereas genomes with 3′-D deletion are expected to be deficient in packaging. The plasmid sequences in the boxed area are detailed below. (b) Structures of plasmids with deletions in the D sequences. pDDwt-CMV-GFP, pDDΔ8-CMV-GFP, pDDΔ12-CMV-GFP, pDDΔ15-CMV-GFP, pDDΔ18-CMV-GFP, and pDDΔ29-CMV-GFP were constructed as described in the Methods. This series of plasmids were otherwise identical except that they contained 0, 8, 12, 15, 18, and 29 base pair (bp) deletion, respectively in a novel 165-bp AAV terminal repeat from one end of the D element. Plasmid pDDΔ18-CMV-GFP(−) was otherwise the same as pDDΔ18-CMV-GFP except that the deleted terminal repeats in the two plasmids were in reversed orientation. pDDΔ18-U1a-GFP and pDDΔ18-U1a-GFP(−) were derived from pDDΔ18-CMV-GFP and pDDΔ18-CMV-GFP(−), respectively by replacing the cytomegalovirus (CMV) promoter with the U1a promoter. GFP, green fluorescent protein; ITR, inverted terminal repeat. Molecular Therapy 2008 16, 494-499DOI: (10.1038/sj.mt.6300397) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 2 Determination of the polarity of adeno-associated virus (AAV) vector genome. AAV vector DNA was extracted and dot-blotted to two identical sets of membrane as described in the Methods. The two sets of membrane were then hybridized each with one of the two complementary oligonucleotides derived from the cytomegalovirus (CMV) promoter, Probe CMV(+) or Probe CMV(−), which detect either the plus-strand or the minus-strand of the AAV DNA genomes. The amount of each polarity of the vector genome was determined by comparison with double-stranded, CMV-promoter plasmid standards loaded on each set of the membrane. GFP, green fluorescent protein. Molecular Therapy 2008 16, 494-499DOI: (10.1038/sj.mt.6300397) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 3 Transduction of mouse muscle by single-polarity adeno-associated virus (AAV) vectors. The following five preparations of AAV vector at a dose of 1011 physical particles per animal were injected into the hindlegs of C57BL/6 mice: AAV-DDΔ18-CMV-GFP, AAV-DDΔ18-CMV-GFP(−), AAV-DDΔ18-CMV-GFP mixed with AAV-DDΔ18-CMV-GFP(−) in a 1:1 ratio, AAV-DDwt-CMV-GFP, and a control AAV-CMV-LacZ. Two weeks later, expression of the green fluorescent protein (GFP) transgene contained in the AAV vectors was imaged as described in the Methods. CMV, cytomegalovirus. Molecular Therapy 2008 16, 494-499DOI: (10.1038/sj.mt.6300397) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 4 Transduction of mouse brain by single-polarity adeno-associated virus (AAV) vectors. The following three preparations of AAV vector at a dose of 1011 physical particles per animal were injected into the striatum of Sprague–Dawley rats: AAV-DDΔ18-CMV-GFP, AAV-DDΔ18-CMV-GFP(−), and AAV-DDΔ18-CMV-GFP mixed with AAV-DDΔ18-CMV-GFP(−) in a 1:1 ratio. Two weeks later, expression of the green fluorescent protein (GFP) transgene contained in the AAV vectors was examined as described in the Methods. CMV, cytomegalovirus. Molecular Therapy 2008 16, 494-499DOI: (10.1038/sj.mt.6300397) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 5 Transduction of mouse liver by single-polarity adeno-associated virus (AAV) green fluorescent protein (GFP) vectors. (a) The following four preparations of AAV vector at a dose of 3 × 1011 vector genome (v.g.) particles per animal were injected into C57BL/6 mice through the portal vein: AAV-DDΔ18-U1a-GFP, AAV-DDΔ18-U1a-GFP(−), AAV-DDΔ18-U1a-GFP mixed with AAV-DDΔ18-U1a-GFP(−) in a 1:1 ratio, and a control AAV-CMV-LacZ. Six weeks later, expression of the GFP transgene from the AAV vectors was directly imaged as described in the Methods. (b) Lower vector doses (1 × 1011 v.g. particles) were identically administered and processed as in a, except that an immunofluorescent staining for GFP was also performed on consecutive sections to confirm the GFP expression. Molecular Therapy 2008 16, 494-499DOI: (10.1038/sj.mt.6300397) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions